Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
Oct 15, 2009

Biocartis to Pocket Roughly $14.9M in Series A Financing

  • Molecular diagnostics firm Biocartis raised €10 million (about $14.94 million) in a Series A equity financing round with a syndicate of life science investors. The primary fields of applications being targeted are analysis of bio-molecules associated with risk factors, early detection, staging, treatment selection, and disease monitoring.

    Based in Lausannes, Switzerland, Biocartis was founded in 2007 to develop a novel molecular diagnostics technology for low-to-highly multiplexed bioanalyte detection. The firm claims that starting from a single, low-volume clinical sample, the platform has the potential to carry out the multiplexed detection and quantification of a large variety of biological molecules including DNA, RNA, proteins, and small molecules.

    The fundraising was led by Amsterdam-based Aescap Venture. Other members of the syndicate are Biovest, KBC Private Equity, Advent Venture Partners, and existing shareholder Benaruca.



Related content

Be sure to take the GEN Poll

Scientifically Studying Ecstasy

MDMA (commonly known as the empathogen “ecstasy”) is classified as a Schedule 1 drug, which is reserved for compounds with no accepted medical use and a high abuse potential. Two researchers from Stanford, however, call for a rigorous scientific exploration of MDMA's effects to identify precisely how the drug works, the data from which could be used to develop therapeutic compounds.

Do you agree that ecstasy should be studied for its potential therapeutic benefits?

More »